Common Liver Enzyme Elevations with Tigecycline
Tigecycline, a glycylcycline antibiotic, commonly causes transient increases in liver enzymes like ALT and AST, affecting 10-20% of patients in clinical trials. These elevations are usually mild (up to 3-5 times upper limit of normal) and resolve after stopping treatment.[1][2]
Patient-Specific Risk Factors
Pre-existing liver conditions amplify risk: patients with chronic hepatitis, cirrhosis, or baseline elevated enzymes (e.g., ALT >2.5x ULN) see higher incidence, up to 30-40%.[2] Age over 65, obesity, and female sex also correlate with greater changes, likely due to slower clearance and higher exposure.[1][3]
Drug Interactions and Concomitant Use
Combining tigecycline with hepatotoxic drugs heightens effects:
- Statins, acetaminophen, or other antibiotics (e.g., azithromycin) increase enzyme spikes via additive stress on hepatocytes.
- CYP3A4 inducers like rifampin may reduce tigecycline levels but paradoxically worsen liver strain in some cases.[2][4]
Avoid in patients on multiple hepatotoxins; monitor ALT/AST weekly.[1]
Dosing and Duration Effects
Higher doses (e.g., 100 mg loading then 50 mg BID) or prolonged use (>14 days) drive more pronounced elevations—up to 25% incidence beyond 2 weeks. Shorter courses (<7 days) show minimal impact.[2][5] IV administration alone; no oral form avoids gut-liver first-pass issues.
Underlying Infection and Disease Factors
Severe infections like intra-abdominal abscesses or ventilator-associated pneumonia, common tigecycline indications, independently raise enzymes (e.g., via sepsis-induced inflammation). Tigecycline's biliary excretion (50% unchanged) may exacerbate cholestasis in biliary infections.[1][3]
Monitoring and Management Tips
Check baseline LFTs; retest at days 7, 14, and end of therapy. Discontinue if ALT >5x ULN or with symptoms like jaundice. No specific antidote; supportive care suffices as changes rarely progress to failure.[1][2]
Sources
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: FDA Label and Clinical Review
[3]: Hepatology Journal Review on Tigecycline Hepatotoxicity
[4]: Drug Interactions Database (Drugs.com)
[5]: Clinical Trials Data (NCT00219495)